Akebia Therapeutics
Development and commercialization of therapeutics for patients with chronic kidney disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | N/A | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (28 %) | 37 % | (33 %) | (18 %) | 24 % | 44 % | 7 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (124 %) | (16 %) | (2 %) | (8 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (132 %) | (32 %) | (27 %) | (43 %) | (8 %) | 7 % | 7 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 69 % | 44 % | 32 % | 24 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with chronic kidney disease (CKD). The company primarily focuses on addressing anemia associated with CKD through its lead product candidate, vadadustat, which is currently undergoing global Phase 3 clinical trials. Akebia serves patients, families, and medical professionals by providing cutting-edge treatments aimed at improving the quality of life for those affected by kidney disease. Operating in the biopharmaceutical market, Akebia's business model involves extensive research and development, clinical trials, and strategic partnerships to bring its therapies to market. Revenue is generated through product sales, licensing agreements, and collaborations with other healthcare organizations. The company is headquartered in Cambridge, MA, and actively participates in major healthcare conferences to present its findings and advancements.
Keywords: biopharmaceutical, chronic kidney disease, anemia, vadadustat, clinical trials, innovative therapies, research and development, strategic partnerships, healthcare, Cambridge MA.
Tech stack
Investments by Akebia Therapeutics
Edit